Irbesartan: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2026-01-06 14:14:46 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
JC Gillis, A Markham
Drugs, 1997
Springer
Synopsis Irbesartan inhibits the activity of angiotensin II (AII) via specific, selective non-competitive antagonism of the AII receptor subtype I (AT1) which mediates most of the known physiological activities of AII. In patients with mild to moderate hypertension, once daily administration of irbesartan 150 or 300mg, with or without adjunctive antihypertensive agents, provides effective 24-hour BP control. Irbesartan reduced BP to a similar extent to enalapril and atenolol and to a significantly greater extent than losartan. The combination of …
